Boehringer's Spiriva inhaler now available throughout the U.S.; Update on Mannkind's inhaled insulin from JP Morgan;

> Boehringer Ingelheim's Spiriva Respimat inhaler is now available by prescription in pharmacies throughout the U.S. Release

> Mannkind's new CEO, Hakan Edstrom, gave an update on its inhaled insulin product at the JP Morgan Healthcare Conference. Afrezza is going to launch in partnership with Sanofi ($SNY). "In terms of the early market initiation, basically, we are looking at the insulin intensification of those patients that have been on a long acting initially to just avoid frequent injections and certainly those that are failing on orals and need to start an insulin therapy," he said. Listen